

Press release

REIG JOFRE AND ZENDAL APPOINTED BY THE EU TO ENSURE VACCINE PRODUCTION CAPACITY IN EUROPE IN CASE OF FUTURE HEALTH EMERGENCIES

June 30, 2023

Barcelona/O Porriño (Spain), The companies [REIG JOFRE](#), (BME:[RJF](#)) a pharmaceutical company listed on the Spanish continuous market, and biotechnology company [CZ VACCINES](#), (part of the Zendal group) signed an agreement with the European Health and Digital Executive Agency (HaDEA) to reserve vaccine production capacity.

The European Commission, through HaDEA, initiated a tender process with the aim of securing a manufacturing and supply network across the EU and EEA to ensure early availability of vaccines in case of a public health emergency. The consortium formed by REIG JOFRE and CZ VACCINES has been one of the four final awardees in this process.

The capacity reservation agreement has been signed with an initial duration of four years. HaDEA has the possibility to extend this agreement for two additional periods, for a maximum total duration of eight years.

The combined capabilities of CZ VACCINES and REIG JOFRE, which ensure an integrated manufacturing process from antigen to the final dosage form of the vaccine, along with their demonstrated experience in crisis management and the availability of cutting-edge technology, have been essential factors in their selection as members of this European vaccine manufacturing network. Both companies have committed to producing and delivering the assigned vaccine doses to the EU territory within a twelve-month timeframe following the activation of an emergency.

CZ VACCINES, part of the Zendal Group, commits to reserving manufacturing capacity in its production area in O Porriño to produce the vaccine active ingredient.

On its part, REIG JOFRE will reserve up to 30% of the maximum annual capacity of its new injectables plant located in Barcelona to meet the program's requirements.

If the reserved capacity is activated due to an emergency, both companies commit to ensuring the supply chain, conducting the technological transfer of the vaccine chosen by HaDEA, and assigning specifically trained technical personnel to meet the demand.

More information

Inma Santa-Pau - Director of Communications and Investor Relations - isantapau@reigjofre.com

www.reigjofre.com



In addition to the revenues derived from this agreement and linked to the reserved manufacturing capacity, REIG JOFRE will continue to strengthen projects, both for clients and its own products, with the aim of achieving maximum production capacity for liquid and lyophilized vials.

REIG JOFRE & CZ VACCINES express their gratitude to the European Commission for the trust placed in both companies in a project of such strategic importance in the field of European citizens' health. Just as they were committed to their teams and technological capabilities during the recent Covid pandemic, they approach this new challenge with awareness of the responsibility undertaken to ensure vaccine supply in the event of a future emergency.

Press release published on the official website of the European Union: [Framework contract signed under EU4Health to guarantee a fast response to future health crises](#)

About ZENDAL

Zendal is the corporate brand of the biopharmaceutical group that brings together eight companies focused on the research, development, manufacturing, and commercialization of human and animal vaccines, as well as other high-value-added products for the healthcare field. The companies under its umbrella include **CZ Vaccines**, Biofabri, Probisearch, Vetia, Petia, Zinereo, Ovejero Laboratories, and Maymó. The company, located in O Porriño, has a team of over 650 highly qualified individuals.

The subsidiary CZ Vaccines is dedicated to the research, development, and large-scale manufacturing of a wide range of viral and bacterial vaccines, as well as other biologics, in its various production facilities.

About REIG JOFRE

REIG JOFRE, founded in 1929 in Barcelona, is dedicated to the research, development, manufacturing, and marketing of pharmaceutical products and food supplements. The company operates in three business units: *Pharmaceutical Technologies* (sterile injectables, lyophilized products, and antibiotics), *Specialty Pharmicare* (dermatology, osteoarticular, women's health, and pediatrics), and *Consumer Healthcare* (food supplements under the brand Forté Pharma and OTC products). REIG JOFRE has 1,213 employees and operates four development and production centers in Europe (two in Toledo, one in Barcelona, and one in Sweden). It has its own companies in eight countries (Spain, France, Portugal, Belgium, Sweden, the United Kingdom, Poland, and Singapore) and 160 business partners in over 70 countries. In 2022, the company's revenue was €271 million.